Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,550 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SAFE Clear all
Completed Not applicable Interventional Results available

SAFE at Home: A Service to Provide Social Engagement to Community-Dwelling Persons With Dementia

NCT05516147
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Dementia, Vascular, Dementia, Mixed
Interventions
SAFE at Home
Behavioral
Lead sponsor
Hopeful Aging
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial

NCT04847349
View directory record Official record
Conditions
Covid19
Interventions
OL-1, standard dose, OL-1, high dose, Placebo
Dietary Supplement
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 30, 2026, 4:25 PM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

NCT05537740
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY3375968, Pembrolizumab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fasting-Mimicking Diet on Skin Health

NCT05564624
View directory record Official record
Conditions
Skin
Interventions
Fasting mimicking diet (FMD)
Other
Lead sponsor
L-Nutra Inc
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional

Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy

NCT00683189
View directory record Official record
Conditions
Metachromatic Leukodystrophy
Interventions
Warfarin
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
1 Year to 10 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2011 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing Testing Strategies for Safe Return to K-12 Schools in an Underserved Population

NCT04875520
View directory record Official record
Conditions
Covid19
Interventions
Screening testing strategy, No screening testing strategy
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
0 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Hazelwood, Missouri • Jennings, Missouri • Saint Ann, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Recruiting Phase 1 Interventional

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

NCT04928677
View directory record Official record
Conditions
Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Interventions
Codrituzumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional

Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care

NCT03537573
View directory record Official record
Conditions
Acute Pain, Headache, Musculoskeletal Pain
Interventions
Usual Care/Guideline, Opioid Justification, Provider Comparison
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
22,616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 30, 2026, 4:25 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Teen Driving Translation Study (NIH)

NCT05696353
View directory record Official record
Conditions
Drive, Recidivism, Communication, Feedback, Psychological
Interventions
In-vehicle Device, Expert-Delivered Parent Communication Training, Peer-Delivered Parent Communication Training
Combination Product · Behavioral
Lead sponsor
Ginger Yang
Other
Eligibility
16 Years to 18 Years
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

NCT05821777
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
LB101
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Denver, Colorado • Sarasota, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

NCT03095781
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Pancreatic Carcinoma
Interventions
XL888, Pembrolizumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04480086
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Mivebresib, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Stony Brook, New York • Cincinnati, Ohio • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 30, 2026, 4:25 PM EDT
Recruiting Phase 3 Interventional

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Not yet recruiting Phase 3 Interventional

CKM For Safe Use of SGLT2i in Type 1 Diabetes

NCT07211802
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Sotagliflozin Low Dose, Sotagliflozin High Dose, Dual Continuous Glucose and Ketone Monitor
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional

Safely Disposing of Surplus Prescription Opioids

NCT03855241
View directory record Official record
Conditions
Opioid Use
Interventions
Informational Sheet, DisposeRx Drug Disposal kit
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 30, 2026, 4:25 PM EDT
Completed No phase listed Observational Results available

ED Lung Protective Ventilation to Reduce Complications

NCT02543554
View directory record Official record
Conditions
Mechanical Ventilation, Ventilator-associated Conditions, ARDS
Interventions
lung protective ventilation
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional

Expect Respect Middle School Randomized Trial

NCT04095429
View directory record Official record
Conditions
Adolescent Behavior, Violence in Adolescence, Group, Peer, Violence, Non-accidental, Violence, Sexual, Violence, Physical, Violence, Domestic, Emotional Abuse, Coping Skills, Communication, Personal
Interventions
Expect Respect, Enhanced Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
11 Years to 15 Years
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 30, 2026, 4:25 PM EDT
Recruiting Phase 1 Interventional

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

NCT06469281
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions
27T51, Cemiplimab, Bevacizumab
Other · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Interventions
REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional Results available

Preventing Risky Drinking in Veterans Treated With Prescription Opioids

NCT02709317
View directory record Official record
Conditions
Pain, Opiates, Alcohol Drinking
Interventions
Prevention Intervention, Brief Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 88 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 30, 2026, 4:25 PM EDT
Recruiting Not applicable Interventional

Supportive Care Intervention for Outpatient Stem Cell Transplant Patients

NCT06564233
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Cancer
Interventions
care.coach Avatar™
Behavioral
Lead sponsor
Victor Wang
Industry
Eligibility
19 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional Results available

Behavioral Insights to Encourage Judicious Prescribing of Opioids

NCT02790476
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Letters
Other
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 30, 2026, 4:25 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
Tafasitamab, Lenalidomide
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Morristown, New Jersey • Dallas, Texas • Olympia, Washington
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Recruiting Not applicable Interventional

Use of ReDS Technology in Patients With Acute Heart Failure

NCT04305717
View directory record Official record
Conditions
Heart Failure, Lung Congestion
Interventions
ReDS-guided strategy
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 30, 2026, 4:25 PM EDT